Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

123.07 -1.58 (-1.27%)
Streaming Delayed Price Updated: 3:56 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity. 
Via Stocktwits
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now ↗
Healthcare stocks have lagged the market for years, but 2026 is looking much better. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma. 
Via Stocktwits
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
Via Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
News headline image
Why Did RGNX Shares Plummet 19% After-Hours Today? ↗
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial. 
Via Stocktwits
News headline image
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases. 
Via Stocktwits
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
Via Stocktwits
Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
Via Stocktwits
IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
Via Stocktwits
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral ↗
Via Stocktwits
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
News headline image
Healthcare Sector Falters: S&P 500's Biggest Loser Amid Broader Market Caution
New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Eaton, FTAI Aviation And More On CNBC&#39;s &#39;Final Trades&#39; ↗
FTAI Aviation (NASDAQ: FTAI) is recommended by investment experts to diversify portfolios beyond tech, while Eaton (NYSE: ETN) and SPDR S&P Biotech ETF (NYSE: XBI) show promising price action. SoFi's... 
Via Benzinga
Topics ETFs Stocks
News headline image
Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. ↗
The SPDR S&P Biotech ETF is a compelling investment option. 
Via The Motley Fool
Topics ETFs Economy Government
News headline image
Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off ↗
Rotating To Healthcare Please click here for an enlarged chart comparing Invesco QQQ Trust Series 1 (NASDAQ: 
Via Benzinga
Topics Economy
News headline image
Taiwan Semiconductor, HealthEquity, Cboe Global Markets And More: CNBC's 'Final Trades' ↗
Stephen Weiss of Short Hills Capital Partners, named Taiwan Semiconductor Manufacturing Company as his final trade. 
Via Benzinga
News headline image
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗
Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
Via Benzinga
Topics ETFs
News headline image
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science. 
Via Stocktwits
Topics Lawsuit
News headline image
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin ↗
As markets enter their strongest stretch, ETFs tied to AI, banking, and healthcare could shine. Here's where investors are finding fresh momentum. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
News headline image
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
Via Stocktwits
News headline image
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.